Trial reportEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology2025
Battery longevity of a helix-fixation dual-chamber leadless pacemaker: results from the AVEIR DR i2i Study.
Trial report in Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05252702 (Aveir Dual-Chamber Leadless i2i IDE Study), which is not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Aveir Dual-Chamber Leadless i2i IDE Study
Who cites it
13 citing papers in PubMed.
- Upgrading expandable leadless pacemakers from single- to dual-chamber.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026Trial
- Atrioventricular synchrony maintained by a dual-chamber leadless pacemaker in real-world conditions.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026Trial
- Efficacy and safety of Lingbao Huxin Dan in the treatment of sick sinus syndrome: a randomized, single-blind, placebo-controlled, crossover trial.Frontiers in cardiovascular medicine · 2026Trial
- Perisinus nodal atrial pacing at the right anterosuperior site using a leadless atrial pacemaker: A case series.HeartRhythm case reports · 2026Article
- Impact of Atrial and Dual-Chamber Leadless Pacing on Subcutaneous Implantable Cardioverter-Defibrillator Screening Eligibility.Journal of cardiovascular electrophysiology · 2026Article
- Variability in Pacemaker Battery Estimates and Performance.Pacing and clinical electrophysiology : PACE · 2026Article
- Computational analysis of intracardiac collision risk and optimal site for right ventricular leadless left bundle branch area pacing: A simulation study.Heart rhythm O2 · 2026Article
- Very high acute pacing thresholds during atrial leadless pacemaker implantation: Feasibility of a current-of-injury-guided release strategy.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2026Article
- Leadless atrial versus transvenous pacing for sinus node dysfunction: 1-year outcomes from the leadless ARRIVE real-world study.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026Article
- Article
- Clinical Considerations Regarding Pacemaker Syndrome Under VVIR Pacing.Journal of arrhythmia · 2025Article
- Getting the most out of dual-chamber leadless pacing: how to prolong battery longevity?Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025Article
- Initial experience with implant of Aveir VR and DR leadless pacemakers in Spain. New insights about battery longevity.Indian pacing and electrophysiology journalArticle
Corrections and comments
- Commented on by
Authors and funding
14 authors.
Funding
Abstract
aimsA dual-chamber leadless pacemaker (LP) system that employs distinct atrial and ventricular LP devices (ALP, VLP) has been introduced to clinical practice. Proprietary, low-energy, implant-to-implant (i2i) communication at each beat enables the devices to maintain synchronous atrioventricular sensing and pacing. We evaluated device longevities and contributing factors, such as i2i communication. METHODS AND
resultsPatients meeting dual-chamber pacing indications received the dual-chamber LP system as part of a prospective, multi-centre, international clinical trial (Aveir DR i2i Study, NCT05252702). Programming and diagnostics were interrogated from all de novo, non-revised, dual-chamber programmed devices at 12 months post-implant. This analysis included 302 patients (65% male; age 70 ± 13 years; weight 80 ± 19 kg; intrinsic heart rate 55 ± 7 bpm; 58% sinus node dysfunction, 27% atrioventricular block). At 12 months, devices were programmed to dual-chamber pacing (DDD(R) or DDI(R)) at a median 60 bpm rate, median 1.25 V pulse amplitude in ALP and 1.5 V in VLP, median 0.4 ms pulse width, and median i2i signal setting level 5 out of 7. Median ALP and VLP remaining battery longevities at 12 months were 4.3 and 9.1 years, with median total ALP and VLP longevities of 5.3 and 9.9 years. Base rate, pulse amplitude, pacing percentage, event rate, impedance, and i2i setting level all exhibited significant correlations with ALP and VLP longevities (P < 0.001). Programming i2i setting levels below 7 produced the greatest longevity savings.
conclusionThe first dual-chamber LP demonstrated adequate projected battery longevity after 12 months of use. Patient-specific device programming considerations, unique to leadless devices, may extend longevity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.